| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 4 securities · may seek to influence control | ||||||
|
Core Scientific, Inc.
13D/A
CORZ · 21874A106
|
4.4% |
4/23/2026
Event 4/23/2026
|
||||
| Two Seas Capital LP | 4.4% | |||||
| Two Seas Capital GP LLC | 4.4% | |||||
| Sina Toussi | 4.4% | |||||
|
Odyssey Marine Exploration, Inc
13D
OMEX · 676118201
|
10.0% |
4/13/2026
Event 4/8/2026
|
||||
| Two Seas Capital LP | 10.0% | |||||
| Two Seas Capital GP LLC | 10.0% | |||||
| Sina Toussi | 10.0% | |||||
|
Indivior PLC
13D/A
INDV · G4766E116
|
4.98% |
12/23/2025
Event 12/23/2025
|
||||
| Two Seas Capital LP | 4.98% | |||||
| Two Seas Capital GP LLC | 4.98% | |||||
| Sina Toussi | 4.98% | |||||
|
Core Scientific, Inc.
13D
CORZ · 21874A106
|
6.3% |
8/8/2025
Event 8/7/2025
|
||||
| Two Seas Capital LP | 6.3% | |||||
| Two Seas Capital GP LLC | 6.3% | |||||
| Sina Toussi | 6.3% | |||||
| Schedule 13G · 12 securities · passive | ||||||
|
SharonAI Holdings Inc.
13G
SHAZ · 778920306
|
6.6% |
11/16/2026
Event 9/30/2026
|
||||
| Two Seas Capital LP | 6.6% | |||||
| Two Seas Capital GP LLC | 6.6% | |||||
| Sina Toussi | 6.6% | |||||
|
Sable Offshore Corp.
13G/A
SOC · 78574H104
|
9.1% |
11/16/2026
Event 9/30/2026
|
||||
| Two Seas Capital LP | 9.1% | |||||
| Two Seas Capital GP LLC | 9.1% | |||||
| Sina Toussi | 9.1% | |||||
|
Quantum Corporation
13G/A
QMCO · 747906600
|
3.8% |
11/16/2026
Event 9/30/2026
|
||||
| Two Seas Capital LP | 3.8% | |||||
| Two Seas Capital GP LLC | 3.8% | |||||
| Sina Toussi | 3.8% | |||||
|
Calumet, Inc. /DE
13G/A
CLMT · 131428104
|
6.0% |
11/16/2026
Event 9/30/2026
|
||||
| Two Seas Capital LP | 6.0% | |||||
| Two Seas Capital GP LLC | 6.0% | |||||
| Sina Toussi | 6.0% | |||||
|
Arbutus Biopharma Corporation
13G/A
ABUS · 03879J100
|
4.1% |
11/16/2026
Event 9/30/2026
|
||||
| Two Seas Capital LP | 4.1% | |||||
| Two Seas Capital GP LLC | 4.1% | |||||
| Sina Toussi | 4.1% | |||||
|
Nektar Therapeutics
13G/A
NKTR · 640268306
|
9.8% |
9/28/2026
Event 9/25/2026
|
||||
| Two Seas Capital LP | 9.8% | |||||
| Two Seas Capital GP LLC | 9.8% | |||||
| Sina Toussi | 9.8% | |||||
|
PAVmed Inc.
13G
PAVM · 70387R502
|
10.0% |
5/15/2026
Event 3/31/2026
|
||||
| Two Seas Capital LP | 10.0% | |||||
| Two Seas Capital GP LLC | 10.0% | |||||
| Sina Toussi | 10.0% | |||||
|
Veradigm Inc.
13G/A
MDRX · 01988P108
|
8.2% |
5/15/2026
Event 3/31/2026
|
||||
| Two Seas Capital LP | 8.2% | |||||
| Two Seas Capital GP LLC | 8.2% | |||||
| Sina Toussi | 8.2% | |||||
|
Avadel Pharmaceuticals plc
13G/A
AVDL · G29687103
|
0% |
2/17/2026
Event 12/31/2025
|
||||
| Two Seas Capital LP | 0% | |||||
| Two Seas Capital GP LLC | 0% | |||||
| Sina Toussi | 0% | |||||
|
Esperion Therapeutics, Inc.
13G/A
ESPR · 29664W105
|
4.7% |
11/14/2025
Event 9/30/2025
|
||||
| Two Seas Capital LP | 4.7% | |||||
| Two Seas Capital GP LLC | 4.7% | |||||
| Sina Toussi | 4.7% | |||||
|
Adaptimmune Therapeutics PLC
13G/A
ADAPY · 00653A107
|
0% |
11/14/2025
Event 9/30/2025
|
||||
| Two Seas Capital LP | 0% | |||||
| Two Seas Capital GP LLC | 0% | |||||
| Sina Toussi | 0% | |||||
|
Gannett Co., Inc.
13G/A
TDAY · 36472T109
|
9.6% |
11/14/2025
Event 9/30/2025
|
||||
| Two Seas Capital LP | 9.6% | |||||
| Two Seas Capital GP LLC | 9.6% | |||||
| Sina Toussi | 9.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.